Effects of Polymorphisms on Plasma Estrogen Concentrations in Women with Breast Cancer Receiving Aromatase Inhibitors Exemestane and Letrozole

Overview

Journal Pharmacogenomics

Specialties Genetics
Pharmacology

Date 2019 Jun 14

PMID 31190621

Citations 4

Authors

Jacqueline M Dempsey

Kelley M Kidwell

Christina L Gersch

Andrea M Pesch

Zeruesenay Desta

Anna Maria Storniolo

Vered Stearns

Todd C Skaar

Daniel F Hayes

N Lynn Henry

James M Rae

Daniel L Hertz

Affiliations

Soon will be listed here.

Abstract

This study tested for associations between polymorphisms and circulating estrogen levels in women with breast cancer treated with letrozole or exemestane. Postmenopausal women with hormone-receptor positive breast cancer were genotyped for (rs4149056) and rs10841753. Pretreatment and on-treatment plasma estrogens and aromatase inhibitor (AI) concentrations were measured. Regression analyses were performed to test for pharmacogenetic associations with estrogens and drug concentrations. was associated with elevated pretreatment estrone sulfate and an increased risk of detectable estrone concentrations after 3 months of AI treatment. These findings suggest polymorphisms may have an effect on estrogenic response to AI treatment, and therefore may adversely impact the anticancer effectiveness of these agents.

Citing Articles

Association between SLCO1B1 genetic polymorphisms and bleeding risk in patients treated with edoxaban.

Han J, Jang E, Yee J, Song T, Kim D, Park J Sci Rep. 2023; 13(1):15967.

PMID: 37749323 PMC: 10520058. DOI: 10.1038/s41598-023-43179-7.

The effect of genetic variation in estrogen transportation and metabolism on the severity of menopause symptoms: A study from the RIGHT 10K cohort.

Kapoor E, Faubion S, Kuhle C, Kling J, Miller V, Fokken S Maturitas. 2023; 176:107797.

PMID: 37595497 PMC: 10478674. DOI: 10.1016/j.maturitas.2023.107797.

Development and Validation of an ADME-Related Gene Signature for Survival, Treatment Outcome and Immune Cell Infiltration in Head and Neck Squamous Cell Carcinoma.

Tang X, Li R, Wu D, Wang Y, Zhao F, Lv R Front Immunol. 2022; 13:905635.

PMID: 35874705 PMC: 9304892. DOI: 10.3389/fimmu.2022.905635.

Genetic Influences in Breast Cancer Drug Resistance.

Daniyal A, Santoso I, Gunawan N, Barliana M, Abdulah R Breast Cancer (Dove Med Press). 2021; 13:59-85.

PMID: 33603458 PMC: 7882715. DOI: 10.2147/BCTT.S284453.

References

Lonning P . The potency and clinical efficacy of aromatase inhibitors across the breast cancer continuum. Ann Oncol. 2010; 22(3):503-514. PMC: 3042921. DOI: 10.1093/annonc/mdq337. View

Ingle J, Buzdar A, Schaid D, Goetz M, Batzler A, Robson M . Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancer. Cancer Res. 2010; 70(8):3278-86. PMC: 2855746. DOI: 10.1158/0008-5472.CAN-09-3024. View

Gregory B, Chen S, Murphy M, Atchley D, Kamdem L . Impact of the OATP1B1 c.521T>C single nucleotide polymorphism on the pharmacokinetics of exemestane in healthy post-menopausal female volunteers. J Clin Pharm Ther. 2017; 42(5):547-553. PMC: 5646416. DOI: 10.1111/jcpt.12569. View

Smiley D, Khalil R . Estrogenic compounds, estrogen receptors and vascular cell signaling in the aging blood vessels. Curr Med Chem. 2009; 16(15):1863-87. PMC: 2852629. DOI: 10.2174/092986709788186093. View

Borrie A, Rose R, Choi Y, Perera F, Read N, Sexton T . Letrozole concentration is associated with CYP2A6 variation but not with arthralgia in patients with breast cancer. Breast Cancer Res Treat. 2018; 172(2):371-379. DOI: 10.1007/s10549-018-4910-z. View

Kadakia K, Kidwell K, Seewald N, Snyder C, Storniolo A, Otte J . Prospective assessment of patient-reported outcomes and estradiol and drug concentrations in patients experiencing toxicity from adjuvant aromatase inhibitors. Breast Cancer Res Treat. 2017; 164(2):411-419. PMC: 5517133. DOI: 10.1007/s10549-017-4260-2. View

Henry N, Giles J, Ang D, Mohan M, Dadabhoy D, Robarge J . Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. Breast Cancer Res Treat. 2007; 111(2):365-72. PMC: 3081690. DOI: 10.1007/s10549-007-9774-6. View

Desta Z, Kreutz Y, Nguyen A, Li L, Skaar T, Kamdem L . Plasma letrozole concentrations in postmenopausal women with breast cancer are associated with CYP2A6 genetic variants, body mass index, and age. Clin Pharmacol Ther. 2011; 90(5):693-700. PMC: 3667657. DOI: 10.1038/clpt.2011.174. View

Geisler J, Haynes B, Anker G, Dowsett M, Lonning P . Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol. 2002; 20(3):751-7. DOI: 10.1200/JCO.2002.20.3.751. View

10.

. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. 2015; 386(10001):1341-1352. DOI: 10.1016/S0140-6736(15)61074-1. View

11.

Ghimenti C, Mello-Grand M, Grosso E, Scatolini M, Regolo L, Zambelli A . Regulation of aromatase expression in breast cancer treated with anastrozole neoadjuvant therapy. Exp Ther Med. 2013; 5(3):902-906. PMC: 3570232. DOI: 10.3892/etm.2012.878. View

12.

Shitara Y . Clinical importance of OATP1B1 and OATP1B3 in drug-drug interactions. Drug Metab Pharmacokinet. 2011; 26(3):220-7. DOI: 10.2133/dmpk.DMPK-10-RV-094. View

13.

Key T, Appleby P, Barnes I, Reeves G . Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst. 2002; 94(8):606-16. DOI: 10.1093/jnci/94.8.606. View

14.

Ramsey L, Moncrieffe H, Smith C, Sudman M, Marion M, Langefeld C . Association of *14 Allele with Poor Response to Methotrexate in Juvenile Idiopathic Arthritis Patients. ACR Open Rheumatol. 2019; 1(1):58-62. PMC: 6858017. DOI: 10.1002/acr2.1008. View

15.

Goss P, Ingle J, Pritchard K, Ellis M, Sledge G, Budd G . Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial. J Clin Oncol. 2013; 31(11):1398-404. PMC: 3612593. DOI: 10.1200/JCO.2012.44.7805. View

16.

Wang L, Ellsworth K, Moon I, Pelleymounter L, Eckloff B, Martin Y . Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors. Cancer Res. 2010; 70(1):319-28. PMC: 2804935. DOI: 10.1158/0008-5472.CAN-09-3224. View

17.

Fuhrman B, Schairer C, Gail M, Boyd-Morin J, Xu X, Sue L . Estrogen metabolism and risk of breast cancer in postmenopausal women. J Natl Cancer Inst. 2012; 104(4):326-39. PMC: 3283536. DOI: 10.1093/jnci/djr531. View

18.

Kalliokoski A, Niemi M . Impact of OATP transporters on pharmacokinetics. Br J Pharmacol. 2009; 158(3):693-705. PMC: 2765590. DOI: 10.1111/j.1476-5381.2009.00430.x. View

19.

Geisler J, King N, Anker G, Ornati G, Di Salle E, Lonning P . In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clin Cancer Res. 1998; 4(9):2089-93. View

20.

Miller W, Larionov A . Understanding the mechanisms of aromatase inhibitor resistance. Breast Cancer Res. 2012; 14(1):201. PMC: 3496110. DOI: 10.1186/bcr2931. View